| ²é¿´: 2020 | »Ø¸´: 27 | |||
| ±¾Ìû²úÉú 2 ¸ö DRDEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
ÀÇÐз÷ÏþÈÙÓþ°æÖ÷ (ÖøÃûдÊÖ)
~~~~
|
[½»Á÷]
½ðÇïÖ®¼Ê»°¡°·áÊÕ¡±£¬Óн±·ÖÏí¾Ñé×ܽá»î¶¯£¬ÆÚ´ýÄãµÄ²ÎÓ룡 ÒÑÓÐ10È˲ÎÓë
|
||
|
½ðÇïÖ®¼Ê»°¡°·áÊÕ¡±£¬Óн±·ÖÏí¾Ñé×ܽá»î¶¯£¬ÆÚ´ýÄãµÄ²ÎÓ룡
¡¾»î¶¯ÄÚÈÝ¡¿
¡¾»î¶¯Ä¿µÄ¡¿: [ Last edited by ÀÇÐз÷Ïþ on 2015-10-19 at 20:11 ] |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸ÌìÖÐÒ½ÖÐҩѧר˶£¬Ï£ÍûÓÐbÇøµÄÀÏʦ¿ÉÒÔ¿¼ÂÇÒ»ÏÂÎÒ
ÒѾÓÐ1È˻ظ´
µ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ128È˻ظ´
ҩѧѧ˶326Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
26Ä격ʿÉêÇë
ÒѾÓÐ20È˻ظ´
Ò©Àíѧ¡¢ÁÙ´²Ò©Ñ§·½Ïò µ÷¼Á
ÒѾÓÐ1È˻ظ´
ÇóÖú ±½Á×Áò°·JP
ÒѾÓÐ0È˻ظ´
100½ð±Ò °¢ÄªÎ÷ÁÖ¿ËÀάËá¼ØÆ¬BPÒ©µäÖÐÌáµ½µÄ¿ËÀάËá¾ÛºÏÎï¾ßÌå½á¹¹Ê½ÊÇɶ£¿
ÒѾÓÐ2È˻ظ´
ÉÅʳ²¹³ä¼ÁºÏ¹æÐÔ½»Á÷
ÒѾÓÐ0È˻ظ´
Ò»Ö¾Ô¸Õã´óҩѧÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
¸ßθßѹ·´Ó¦ÇóÖú
ÒѾÓÐ4È˻ظ´

ÀÇÐз÷Ïþ
ÈÙÓþ°æÖ÷ (ÖøÃûдÊÖ)
~~~~
- DRDEPI: 13
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.045
- ½ð±Ò: 10341.8
- É¢½ð: 619
- ºì»¨: 57
- Ìû×Ó: 1289
- ÔÚÏß: 877.3Сʱ
- ³æºÅ: 1037685
- ×¢²á: 2010-06-07
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
- ¹ÜϽ: ÐÂÒ©Ñз¢
|
»î¶¯ºÜ¼òµ¥£¬´ó¼Ò²»ÒªÏëÌ«¸´ÔÓàÞ£¬²»Óó¤Æª´óÂÛ£¬¿ÉÒÔ·ÖÏíÏÂ×î½üÕÆÎÕµÄС¼¼ÇÉÖ®ÀàµÄ£¬»òÕß¼òµ¥µÄһЩ¾Ñé°É¡£ ʾÀý£º ÒÔǰ֪µÀdrugfuture¿ÉÒÔ²éÕÒ»¯ºÏÎïµÄºÏ³É¹¤ÒÕ·Ïߣ¬Í¨¹ýÒýÓõÄרÀûÀ´×·ËÝÔÑеϝºÏÎïרÀûµÈµÈ¡£ ×î½ü·¢ÏÖÒ©¶ÉÍøÒ²ÊǸö²»´íµÄÍøÕ¾£¬³ýÁË×ܽá³öһЩ¾µäµÄ¹¤ÒÕ·Ïߣ¬»¹¶ÔÅú×¼ÉÏÊеÄÒ©ÎïÖеÄÔÓÖʽøÐÐÁËÁо٣¬°üÀ¨ÔÓÖʵϝºÏÎï½á¹¹Å¶¡£¶ÔÓÚ×ö·ÂÖÆÒ©µÄÁ¢Ïîµ÷ÑУ¬»òÕß¶ÔÓÚÉ걨×ÊÁÏÖÐ3.2.S.2.6Öй¤ÒÕ·ÏßµÄÑ¡Ôñ¶¼Óзdz£²»´íµÄ½è¼ø¼ÛÖµ¡£ |

ÁèÓîÀ׳Ø
³¬¼¶°æÖ÷ (ÎÄѧ̩¶·)
Сľ³æ¿ÆÑдóʹ\(^o^)/~
- DRDEPI: 1
- Ó¦Öú: 758 (²©ºó)
- ¹ó±ö: 161.802
- ½ð±Ò: 301183
- É¢½ð: 91930
- ºì»¨: 1119
- ɳ·¢: 3434
- Ìû×Ó: 93050
- ÔÚÏß: 54969.6Сʱ
- ³æºÅ: 659100
- ×¢²á: 2008-11-21
- ÐÔ±ð: GG
- רҵ: ÉúÎﻯѧ
- ¹ÜϽ: ¿ÆÑÐÉú»îÇø

News
ר¼Ò¹ËÎÊ (Ö°Òµ×÷¼Ò)
- DRDEPI: 6
- Ó¦Öú: 366 (˶ʿ)
- ¹ó±ö: 0.025
- ½ð±Ò: 5971.2
- É¢½ð: 3206
- ºì»¨: 155
- ɳ·¢: 24
- Ìû×Ó: 4826
- ÔÚÏß: 677.4Сʱ
- ³æºÅ: 1205015
- ×¢²á: 2011-02-17
- ÐÔ±ð: GG
- רҵ: É«Æ×·ÖÎö
- ¹ÜϽ: ÉúÎïÒ½Ò©Çø
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÀÇÐз÷Ïþ: ½ð±Ò+8, ¸Ðл֧³Ö£¬¸Ðл½¨Ò飬»î¶¯µÄÆø·ÕÒ²µÃ¶àÑöÕÌÄãÃÇÕâЩÓÅÐãµÄÀÏÕ½ÓѰ¡£¡¿ÉÄÜ´ó¼Ò°Ñ»î¶¯Ï븴ÔÓÁ˰ɣ¬ÆäʵһÁ½¾ä»°ÄÜ˵Ã÷°×µÄÒ»¸ö¾Ñé¶¼ÄÜÓдóÁ¿±Ò±Ò½±ÀøµÄO(¡É_¡É)O~ 2015-10-11 11:42:23
|
Ö§³ÖÖ§³Ö£¬°æÄÚ³æÓѲÎÓë»ý¼«·ÖÏíÒÔ¼°ÌÖÂÛµÄÈÈÇé²»ÊǺܸߡ£ÎÒ¾õµÃÐèÒª¶à¾ÙÐÐÏà¹ØµÄ½»Á÷·ÖÏí»î¶¯£¬ÁªÂçһȺԸÒâ½»Á÷·ÖÏí²¢ÎªÐ¡Ä¾³æµÄÐÂÒ©Ñз¢°å¿éÁ¼ºÃ·¢Õ¹¾¡Î¢±¡Ö®Á¦µÄ³æ³æ¡£ °æÖ÷¸üÓ¦¸Ã´øÍ·£¬½ð±Ò¾Í²»ÒªÁߨÄÁË¡£ ![]() |

News
ר¼Ò¹ËÎÊ (Ö°Òµ×÷¼Ò)
- DRDEPI: 6
- Ó¦Öú: 366 (˶ʿ)
- ¹ó±ö: 0.025
- ½ð±Ò: 5971.2
- É¢½ð: 3206
- ºì»¨: 155
- ɳ·¢: 24
- Ìû×Ó: 4826
- ÔÚÏß: 677.4Сʱ
- ³æºÅ: 1205015
- ×¢²á: 2011-02-17
- ÐÔ±ð: GG
- רҵ: É«Æ×·ÖÎö
- ¹ÜϽ: ÉúÎïÒ½Ò©Çø

ÀÇÐз÷Ïþ
ÈÙÓþ°æÖ÷ (ÖøÃûдÊÖ)
~~~~
- DRDEPI: 13
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.045
- ½ð±Ò: 10341.8
- É¢½ð: 619
- ºì»¨: 57
- Ìû×Ó: 1289
- ÔÚÏß: 877.3Сʱ
- ³æºÅ: 1037685
- ×¢²á: 2010-06-07
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
- ¹ÜϽ: ÐÂÒ©Ñз¢

News
ר¼Ò¹ËÎÊ (Ö°Òµ×÷¼Ò)
- DRDEPI: 6
- Ó¦Öú: 366 (˶ʿ)
- ¹ó±ö: 0.025
- ½ð±Ò: 5971.2
- É¢½ð: 3206
- ºì»¨: 155
- ɳ·¢: 24
- Ìû×Ó: 4826
- ÔÚÏß: 677.4Сʱ
- ³æºÅ: 1205015
- ×¢²á: 2011-02-17
- ÐÔ±ð: GG
- רҵ: É«Æ×·ÖÎö
- ¹ÜϽ: ÉúÎïÒ½Ò©Çø

ÀÇÐз÷Ïþ
ÈÙÓþ°æÖ÷ (ÖøÃûдÊÖ)
~~~~
- DRDEPI: 13
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.045
- ½ð±Ò: 10341.8
- É¢½ð: 619
- ºì»¨: 57
- Ìû×Ó: 1289
- ÔÚÏß: 877.3Сʱ
- ³æºÅ: 1037685
- ×¢²á: 2010-06-07
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
- ¹ÜϽ: ÐÂÒ©Ñз¢

ÀÇÐз÷Ïþ
ÈÙÓþ°æÖ÷ (ÖøÃûдÊÖ)
~~~~
- DRDEPI: 13
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.045
- ½ð±Ò: 10341.8
- É¢½ð: 619
- ºì»¨: 57
- Ìû×Ó: 1289
- ÔÚÏß: 877.3Сʱ
- ³æºÅ: 1037685
- ×¢²á: 2010-06-07
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
- ¹ÜϽ: ÐÂÒ©Ñз¢

ÀÇÐз÷Ïþ
ÈÙÓþ°æÖ÷ (ÖøÃûдÊÖ)
~~~~
- DRDEPI: 13
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.045
- ½ð±Ò: 10341.8
- É¢½ð: 619
- ºì»¨: 57
- Ìû×Ó: 1289
- ÔÚÏß: 877.3Сʱ
- ³æºÅ: 1037685
- ×¢²á: 2010-06-07
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
- ¹ÜϽ: ÐÂÒ©Ñз¢
|
ÃÀ¹úGDUFAÖÐÁ¢¾íÉó²é£¨GDUFA INITIAL COMPLETENESS ASSESSMENT CHECKLIST FOR TYPE II API DMFs£©µÄÆÀÉó½¨Ò飬ͬʱҪ½áºÏ²»½ÓÊܱê×¼ANDA Submissions ¨CRefuse-to-Receive Standards Guidance for Industry£º 3.2.S.2.1 Contains complete Manufacturer Information on the following for each site: Note: If a late stage intermediate has been outsourced, detailed information regarding the source for each supplier needs to be provided in section 2.3. Separate facilities used for release testing of the API and for additional processing (e.g. micronization) should also be listed. Central File Number or Facility Establishment Identifier numbers should be provided if available. 3.2.S.2.2 Contains Description of Manufacturing Process and Process Controls addressing the following: Note: DMF will not be considered complete for review requirements if the complete process is not included in the DMF or by appropriate reference to another DMF. If the firm chooses intermediates as ¡°starting materials¡± a determination should be made if information is provided in the DMF to adequately evaluate their controls and effect on the drug substance quality and purity. 3.2.S.2.3 Contains information on the Control of Materials, as follows: Note: Specification, analytical protocol and representative CoA of each reagent/solvent should be provided. 3.2.S.2.4 Contains information for Controls of Critical Steps and Intermediates as follows: For sterile APIs. 3.2.S.4 Information is provided to support the Control of the Drug Substance as follows: Method validation reports may be included in section 3.2.R.3.S. |

















»Ø¸´´ËÂ¥
News